Abera is developing the next generation vaccines and immunotherapies based on our proprietary vaccine delivery platform.
Abera’s proprietary vaccine delivery platform – BERA, enables high-level multivalent presentation of recombinant antigens on bacterial Outer Membrane Vesicles (OMVs) for strong stimulation of the immune system.
Abera develops vaccine candidates based its technology – BERA. The main candidate is a universal pneumococcal vaccine candidate and the company explores applications in immunotherapy.
Abera is taking Outer Membrane Vesicle technology to the next level by decorating them with high levels of pathogen specific antigens to efficient vaccine candidates.
Abera combines existing technologies, known antigens and break-through improvements with over 30 years of microbiological experience to create innovative vaccines.
Abera is taking Outer Membrane Vesicle technology to the next level by decorating them with high levels of pathogen specific antigens to create efficient vaccine candidates.
Abera combines existing technologies, known antigens and break-through improvements with over 30 years of microbiological experiences into new, innovative vaccines.
Abera Bioscience AB has received so-called Notice of Allowance of the company’s patent application “ Fusion polypeptides comprising one or more inclusion body tags, methods
The vaccine platform developed by Abera Bioscience AB (“Abera” or “the Company”) has been used in a collaboration between researchers at Johns Hopkins University School
Årsstämma 2021 i Abera Bioscience AB (”Abera” eller ”Bolaget”) hölls den 9 juni 2021. Mot bakgrund av COVID-19-pandemin genomfördes årsstämman enbart genom poströstning med stöd
Abera is dedicated to the development of novel vaccines to save lives and increase health globally.
Get in contact with us via the contact form or email: info@aberabio.com
Abera Bioscience is a platform and vaccine development company based on over 30 years of research in the medical, molecular and microbiological field. Abera was founded in 2012 as a spin-out from the Swedish protein production company Xbrane Bioscience.